Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

InMed Pharmaceuticals Inc. (C:IN)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: SUITE 310, 815 W. HASTINGS STREET
Tel: N/A
IR: See website
Key People
William James Garner
Independent Chairman of the Board
Eric A. Adams
President, Chief Executive Officer, Director
Bruce S. Colwill
Chief Financial Officer, Secretary
Eric Chih-Hsien Hsu
Senior Vice President - Preclinical Research and Development
Alexandra D.J. Mancini
Senior Vice President - Clinical and Regulatory Affairs
Michael Henry Woudenberg
Vice President - Chemistry, Manufacturing & Controls
Business Overview
InMed Pharmaceuticals Inc. is a clinical stage pharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. The Company is engaged in developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. It is also developing an integrated cannabinoid manufacturing system for pharmaceutical-grade cannabinoids, called IntegraSyn, as well as multiple cannabinoid-based medications that target diseases with unmet medical needs. The Company's two product candidates: INM-755, for the treatment of Epidermolysis Bullosa (EB), and INM-088, for the treatment of glaucoma. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to EB. INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.
Financial Overview
For the six months ended 31 March 2021, InMedPharmaceuticals Inc revenues was not reported. Net lossincreased 18% to $5.3M. Higher net loss reflects Generaland administrative - Balancing v increase of 30% to $2.2M(expense), Finance expense increase from $0K to $360K(expense), Foreign exchange gain (loss) decrease from $127K(income) to $166K (expense).
Employees: 13 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $9.07M as of Mar 31, 2021
Annual revenue (TTM): $0.00M as of Mar 31, 2021
EBITDA (TTM): -$8.04M as of Mar 31, 2021
Net annual income (TTM): -$8.62M as of Mar 31, 2021
Free cash flow (TTM): -$9.14M as of Mar 31, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 8,050,707 as of Mar 31, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization